NMRD | Jotup

AEP Completes Sale of New Mexico Solar Assets

Retrieved on:

Tuesday, February 27, 2024

American Electric Power, AEP, Multimedia, Exu, Sale, Federal Energy Regulatory Commission, Carbon, Electricity, NMRD, Renewable energy

COLUMBUS, Ohio, Feb. 27, 2024 /PRNewswire/ -- American Electric Power (Nasdaq: AEP) has completed the sale of its 50% interest in New Mexico Renewable Development, LLC (NMRD) to Exus North America Holdings, LLC (Exus).

Key Points:

COLUMBUS, Ohio, Feb. 27, 2024 /PRNewswire/ -- American Electric Power (Nasdaq: AEP) has completed the sale of its 50% interest in New Mexico Renewable Development, LLC (NMRD) to Exus North America Holdings, LLC (Exus).
AEP began the sale process in June 2023 and received necessary regulatory approval from the Federal Energy Regulatory Commission, New Mexico regulatory approvals associated with one of NMRD's projects and clearance under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.
The sale portfolio includes nine operating solar developments totaling 185 MW and six projects under development with an estimated output of 440 MW.
AEP also owns AEP Energy, which provides innovative competitive energy solutions nationwide.

Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

Retrieved on:

Wednesday, December 13, 2023

NMRD

Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.

Key Points:

Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.
The Company plans to continue with its commercial endeavours while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearing Panel’s decision.

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth

Retrieved on:

Tuesday, November 21, 2023

Nemaura Medical, NMRD, Security (finance)

Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans.

Key Points:

Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans.
Recognizing the challenges associated with equity sales, particularly in the small-cap landscape on the Nasdaq, Nemaura Medical has proactively pursued a funding strategy that minimizes dilution and, the Company believes, aligns with the best interests of its valued shareholders.
This $10 million credit facility, structured to be non-dilutive, empowers the Company to draw down a maximum of $1 million per month, providing a steady and controlled infusion of capital to support Nemaura Medical’s commercialization initiatives.
Dilution has long been a concern for public companies, and the Company believes that this credit facility not only addresses this concern but also positions Nemaura Medical for strategic growth.

AEP SIGNS AGREEMENT TO SELL NEW MEXICO SOLAR ASSETS

Retrieved on:

Tuesday, December 26, 2023

COLUMBUS, Ohio, Dec. 26, 2023 /PRNewswire/ -- American Electric Power (Nasdaq: AEP) has entered into an agreement to sell its 50% interest in New Mexico Renewable Development, LLC (NMRD) to Exus North America Holdings, LLC (Exus).

Key Points:

COLUMBUS, Ohio, Dec. 26, 2023 /PRNewswire/ -- American Electric Power (Nasdaq: AEP) has entered into an agreement to sell its 50% interest in New Mexico Renewable Development, LLC (NMRD) to Exus North America Holdings, LLC (Exus).
AEP and PNM Resources, which also owns 50% of NMRD, plan to sell the portfolio of 15 solar projects totaling 625 megawatts (MW) to Exus for approximately $230 million subject to true-up adjustments at close.
The sale is expected to close in February 2024 and will not have a material impact on financial results.
AEP is investing $43 billion over the next five years to make the electric grid cleaner and more reliable.

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update

Retrieved on:

Monday, November 13, 2023

Food, NMRD, Research, KSA, TP, Marketing, Nemaura Medical, Prediabetes, Kingdom, Cryptocurrency

Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended September 30, 2023 and provided a business update.

Key Points:

Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended September 30, 2023 and provided a business update.
The Company continued to support its UK licensee with its endeavours to obtain reimbursement for the sensors in the UK.
Advanced development of the Company’s BEATdiabetes offering in readiness for a commercial launch in due course.
Research and development (“R&D”) expenses were $491,803 and $257,061 for the three months ended September 30, 2023 and 2022, respectively.

Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.

Retrieved on:

Tuesday, September 26, 2023

CGM, Intelligence, NMRD, Medical device, AI

(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai Rozanov as strategic adviser in AI development.

Key Points:

(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai Rozanov as strategic adviser in AI development.
The appointment of Mr Rozanov solidifies the Company’s expertise in the growing AI sector, at a time when AI developments in healthcare are gathering pace.
The Company is now well placed to further integrate data from its CGM to create tailored programs that can make tailored personalised recommendations.
Deeper personalised insights better engage users, and the capability of AI means this can be scaled efficiently”.

Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference

Retrieved on:

Monday, September 18, 2023

Growth, NMRD, Nemaura Medical, Medical device, A.I

Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present business updates and developments at the Maxim Group Emerging Growth in A.I., virtual conference.

Key Points:

Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present business updates and developments at the Maxim Group Emerging Growth in A.I., virtual conference.
The presentation will take place at 11am Eastern time on 27 September 2023.
Register for the conference here: www.m-vest.com

Weight-loss Programs Level Up With Smart Wearable Devices

Retrieved on:

Friday, September 15, 2023

NEW YORK, Sept. 15, 2023 /PRNewswire/ -- The wearable technology market has evolved in recent years into a major tech segment, in large part thanks to consumer market growth which is driven by sales of smartwatches. Major companies like Apple and Samsung are heavily involved in the innovation of wearable devices, which are now capable of performing a wide range of features including cellular connectivity, health monitoring, contactless payment and more. Due to the advanced health monitoring features found in the devices, the wearable technology market is now playing an important role in the medical sector as well. In recent years, the devices have allowed healthcare providers to remotely monitor a patient's various physiological parameters. The most commonly measured data include vital signs such as heart rate, blood pressure, number of calories burned during a day, sleep quality and oxygen level in the blood. Nemaura Medical Inc. (NASDAQ: NMRD), Planet Fitness, Inc. (NYSE: PLNT), WW International, Inc. (NASDAQ: WW), Garmin Ltd. (NYSE: GRMN), iRhythm Technologies, Inc. (NASDAQ: IRTC)

Key Points:

Due to the advanced health monitoring features found in the devices, the wearable technology market is now playing an important role in the medical sector as well.
In recent years, the devices have allowed healthcare providers to remotely monitor a patient's various physiological parameters.
Nemaura Medical Inc. (NASDAQ: NMRD) announced breaking news earlier this week regarding, "interim results from its metabolic health program.
The high medical needs designation in Japan is granted to innovative devices recognized as having high medical utility for significant diseases.

Weight-loss Programs Level Up With Smart Wearable Devices

Retrieved on:

Friday, September 15, 2023

NEW YORK, Sept. 15, 2023 /PRNewswire/ -- The wearable technology market has evolved in recent years into a major tech segment, in large part thanks to consumer market growth which is driven by sales of smartwatches. Major companies like Apple and Samsung are heavily involved in the innovation of wearable devices, which are now capable of performing a wide range of features including cellular connectivity, health monitoring, contactless payment and more. Due to the advanced health monitoring features found in the devices, the wearable technology market is now playing an important role in the medical sector as well. In recent years, the devices have allowed healthcare providers to remotely monitor a patient's various physiological parameters. The most commonly measured data include vital signs such as heart rate, blood pressure, number of calories burned during a day, sleep quality and oxygen level in the blood. Nemaura Medical Inc. (NASDAQ: NMRD), Planet Fitness, Inc. (NYSE: PLNT), WW International, Inc. (NASDAQ: WW), Garmin Ltd. (NYSE: GRMN), iRhythm Technologies, Inc. (NASDAQ: IRTC)

Key Points:

Due to the advanced health monitoring features found in the devices, the wearable technology market is now playing an important role in the medical sector as well.
In recent years, the devices have allowed healthcare providers to remotely monitor a patient's various physiological parameters.
Nemaura Medical Inc. (NASDAQ: NMRD) announced breaking news earlier this week regarding, "interim results from its metabolic health program.
The high medical needs designation in Japan is granted to innovative devices recognized as having high medical utility for significant diseases.

Nemaura Medical Provides Update on Nasdaq Compliance Status and Process

Retrieved on:

Thursday, September 14, 2023

National Health Service, Calendar, Nemaura Medical, SFDA, Panel, Hearing, Staff, NMRD, UK, Food, Pharmaceutical industry

LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .

Key Points:

LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .
(Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provided an update regarding the status of its compliance with Nasdaq continued listed standards and anticipated next steps to maintain its listing on The Nasdaq Capital Market.
The Company plans to timely request such hearing and is considering all options available to it to regain compliance and maintain its listing on The Nasdaq Capital Market.
Dr Faz Chowdhury, the Company’s Chief Executive Officer, commented, “We are hopeful that there will be a positive outcome from a hearing before the Panel.